We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And just like i said the Q&A would be released, plus a video out shortly, swiftly followed by the Japanese tie up...… Preclinical time line -
Repeated dose toxicity studies in one rodent and one non-rodent model
Should equal or exceed the duration of Phase I/II studies: (minimum 2 weeks, maximum 12 months; generally 1-3 months for biotech-derived products )
To support Phase III:
1 month
3 months
6 months
Japanese pharma agreement May...should be completed between June-November.... Soooooo this is going to be an exceptional Q4 in Valirx history. The next phase will be partnered for 201, to what extent? Suzy just said in the Q&A that the phase 2 study will now include other cancers. The 4mg dose had a higher count in human blood than the 100mg in rats. So why try higher? 201 has an excellent safety and tolerability so that's amazing data now for 301 and bc201. Amazing results after all? 30% success rate for marketed cancer drugs, 54.5% for 201. This is going to go ballistic. Well done Suzy and all involved.
A number of major cancer drugs have been approved on the back of response rates of around 30%. We
are therefore very encouraged that we have good early data for VAL201.
I'm not a statistician - but i make that a positive result in over 50% of the patients.
Its meaningful in the sense that these eleven patients would not have any treatment normally , so the cancer would run its course in all 11 patients. Using the treatment, six of the patients responded to the drug in a positive manner, and unfortunately the remainder did not. I know which group i would prefer to be in.
no
Can a nominal response in six out of 11 patients be considered meaningful in any way? Is there a statistician in the house?
We have worked hard over the past few months to ensure our communications are accurate transparent
and timely. The RNS we released yesterday about our headline results was a major milestone for ValiRx and
my intent was to ensure that all shareholders received a clear, fact-based up-date on the phase I/II clinical
trial of VAL201, within the promised timeframe. To repeat the essence of my comments in the RNS, the results are exciting and the culmination of a lot of
hard work by everyone involved in the trial. The data for this first clinical trial of VAL201 has been generated
using the utmost caution in sequentially dosing patients and has taken some considerable time. The
headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug with
a favourable side effect profile. In light of this and the positive response rate we intend to share these
results with potential industry partners to evaluate options for further clinical development of VAL201. Our ultimate goal is captured well in the words of our Medical Monitor, Professor Alan Boyd: “Development
of effective treatments with low-side effects for patients with prostate cancer who have relapsed after
radiotherapy is essential and will improve the lives of patients during treatment.” Best wishes,
Suzy
Dr Suzanne Dilly
It’s on the q and a just posted.
Exceptional results- Not just good
https://www.valirx.com/wp-content/uploads/2020/09/VAL-September-Answers-final.pdf
Eyeguy, out of curiosity where di you get the 30% from?
Like to know what Xtandi is, if anyone knows?
No placing. All cashed up.
Higher response rate than commercial cancer drugs
Boom
Thanks Borsaci, so everything on track, speaking to partners for JV or trade sale now, who have been following progress since the start of 201 proceedings.
Brilliant q and a by Susie
- No placing as they need a general meeting for that
- commercial cancer drugs have Response rate of 30%. VAL got 54.5
Boom
https://www.valirx.com/wp-content/uploads/2020/09/VAL-September-Answers-final.pdf
We appreciate that theresults can be perceived as being very technical to investorsless familiar with theprocesses of clinical trials.Therefore,we willbe using interviews and videos to ensure the information isshared as widely as possible. All such media will be accessible on ourwebsite andwill be signposted viathe Company LinkedIn account.
Now that we have theheadlineresults from the VAL201 clinical trial, we will beprovidingupdatestoourindustry contacts and taking a decision on the best route forward forfurther development of VAL201.All possibilities will be explored with potential partners, including Joint Venture arrangements, whichcould see a partner funding a larger trial in a ValiRx subsidiary; out-licensing, which could see ValiRxreceive a combination of upfront, milestone and royalty payments; or an outright sale, which would seea one-off payment to ValiRx.As is typical in the biotech industry, we have been meeting with potential partnersthroughout thedevelopmentof VAL201 and judging their level of interest.We now intend to progress discussions withselected contacts.The clinical trial closedownprocess is ongoing, and full details of the results are still being assembled intothe Clinical Study Report. When this report is complete,whichisexpectedduring Q4 2020, this will besubmitted to the regulators, the MHRA, as part of the formal trial process. At this time, public databases,such as that held on clinicaltrials.gov will also be updated. If any items of particular general interestemerge from the data at this stage, they will immediately be released via a Company announcement,anddisseminatedthroughpeerreviewedpublicationandpresentationsasappropriate.
Just posted by Suzy
Ho and once and for all they can’t place anymore share be f ing told you derampers.